Physician profile
Alberto D Cuartas
NPI 1740381169
$3,873.51
in general payments reported to CMS, 2019-2025
34 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $404 · 2021: $11.50 · 2022: $531 · 2023: $407 · 2024: $144 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.17 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $653.15 | 2019-2024 | Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals Lp | $485.00 | 2019-2023 | Enhertu |
| Merck Sharp & Dohme LLC | $460.93 | 2019-2025 | Lynparza, Keytruda |
| Janssen Biotech, INC. | $367.20 | 2019-2025 | Erleada, Akeega, Balversa |
| Genentech USA, INC. | $248.78 | 2019-2023 | Polivy, Lunsumio |
| Pfizer INC. | $227.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $212.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $198.18 | 2019-2022 | |
| Celgene Corporation | $108.35 | 2019-2022 | |
| Amgen INC. | $107.42 | 2019-2023 | Kyprolis |
| Eisai INC. | $100.51 | 2019-2020 | |
| Genzyme Corporation | $91.69 | 2019-2020 | |
| Lilly USA, LLC | $52.17 | 2019 | |
| Janssen Scientific Affairs, LLC | $51.58 | 2019 | |
| Seagen INC. | $49.72 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $48.07 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $46.81 | 2019-2020 | |
| Astellas Pharma US INC | $46.09 | 2019-2020 | |
| Sobi, INC | $34.26 | 2023 | |
| Daiichi Sankyo INC. | $33.08 | 2019-2020 | |
| Taiho Oncology, INC. | $31.51 | 2019 | |
| Pharmacosmos Therapeutics INC. | $25.86 | 2025 | Monoferric |
| Abbvie INC. | $25.00 | 2019 | |
| Array Biopharma INC | $24.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.25 | 2019 | |
| Emd Serono, INC. | $16.59 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.05 | 2019 | |
| Exelixis INC. | $15.85 | 2019 | |
| Tactile Systems Technology INC | $14.88 | 2020 | |
| Karyopharm Therapeutics INC. | $13.62 | 2020 | |
| Puma Biotechnology, INC. | $11.91 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Clovis Oncology, INC. | $7.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Cuartas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.